Kangtai Biotech announced that in the first half of 2026, it achieved operating income of 1,273 billion yuan, a year-on-year decrease of 8.55%; net profit attributable to shareholders of listed companies was 50,3861 million yuan, an increase of 34.25% over the previous year. Overseas business revenue in the first half of the year was 595.686 million yuan, an increase of 197.58% over the previous year. In terms of research and development, the quadrivalent influenza virus lysis vaccine and the adsorbed tetanus vaccine have obtained drug registration approval, and various vaccines under development are advancing clinical trials. The company plans to implement semi-annual equity distribution in 2026, with 0.27 yuan for every 10 shares, and a cash dividend of 30 million yuan, accounting for 59.85% of the current net profit to mother.

Kangtai Biotech announced that in the first half of 2026, it achieved operating income of 1,273 billion yuan, a year-on-year decrease of 8.55%; net profit attributable to shareholders of listed companies was 50,3861 million yuan, an increase of 34.25% over the previous year. Overseas business revenue in the first half of the year was 595.686 million yuan, an increase of 197.58% over the previous year. In terms of research and development, the quadrivalent influenza virus lysis vaccine and the adsorbed tetanus vaccine have obtained drug registration approval, and various vaccines under development are advancing clinical trials. The company plans to implement semi-annual equity distribution in 2026, with 0.27 yuan for every 10 shares, and a cash dividend of 30 million yuan, accounting for 59.85% of the current net profit to mother.